ACE2 and COVID-19: There is currently minimal evidence to suggest any preventive advantage of genetic or non-genetic adaptation to high-altitude hypoxia, including the idea that hypoxia-mediated variations in ACE2 expression or ACE2 variants in certain population groups may be related to illness causation or severity of COVID-19 [22].